Corvus Pharmaceuticals, Inc.(CRVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRVS Corvus Pharmaceuticals, Inc.

休市中 05-01 16:00:00 EDT

15.46

+0.27

+1.78%

盘后15.31

-0.15-0.97%

19:48 EDT

最高15.62	最低14.87	成交量86.21万
今开15.08	昨收15.19	日振幅4.97%
总市值12.95亿	流通市值10.39亿	总股本8,377万
成交额1,329万	换手率1.28%	流通股本6,720万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRVS","market":"US","secType":"STK","nameCN":"Corvus Pharmaceuticals, Inc.","latestPrice":15.46,"timestamp":1777665600000,"preClose":15.19,"halted":0,"volume":862068,"hourTrading":{"tag":"盘后","latestPrice":15.31,"preClose":15.46,"latestTime":"19:48 EDT","volume":11321,"amount":174958.6266,"timestamp":1777679289379,"change":-0.15,"changeRate":-0.009702,"amplitude":0.009702},"delay":0,"changeRate":0.017774851876234454,"floatShares":67198000,"shares":83767700,"eps":-0.53,"marketStatus":"休市中","change":0.27,"latestTime":"05-01 16:00:00 EDT","open":15.08,"high":15.62,"low":14.865,"amount":13288958.392212002,"amplitude":0.049704,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.53,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1458705600000,"exchange":"NASDAQ","adjPreClose":15.19,"preHourTrading":{"tag":"盘前","latestPrice":15.06,"preClose":15.19,"latestTime":"09:29 EDT","volume":12493,"amount":190006.78657999999,"timestamp":1777642199999,"change":-0.13,"changeRate":-0.008558,"amplitude":0.094799},"postHourTrading":{"tag":"盘后","latestPrice":15.31,"preClose":15.46,"latestTime":"19:48 EDT","volume":11321,"amount":174958.6266,"timestamp":1777679289379,"change":-0.15,"changeRate":-0.009702,"amplitude":0.009702},"volumeRatio":0.6879401766963686,"impliedVol":0.9866,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/CRVS/wiki","defaultTab":"wiki","newsList":[{"id":"1113775452","title":"财报前瞻｜Corvus Pharmaceuticals, Inc.本季度营收预计持平为0，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1113775452","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113775452?lang=zh_cn&edition=full","pubTime":"2026-05-01 01:05","pubTimestamp":1777568717,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals, Inc.将于2026年05月07日发布最新季度财报，市场普遍关注费用端走势与现金消耗节奏对利润的影响。Corvus Pharmaceuticals, Inc.的估值驱动更多来自研发推进与临床数据读出，而非短期财务指标。公开分析评论对Corvus Pharmaceuticals, Inc.的短期观点以谨慎为主，多数机构认为在无商品化收入背景下，本季度营收预计维持0.00美元，利润指标仍取决于研发与管理费用的节奏，预计调整后每股收益约-0.14美元、EBIT约-1,407.44万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Corvus Pharmaceuticals, Inc.本季度营收预计持平为0，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118419985","title":"Corvus制药任命陈安德博士加入董事会，强化免疫疗法研发实力","url":"https://stock-news.laohu8.com/highlight/detail?id=1118419985","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118419985?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:35","pubTimestamp":1776944140,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Corvus Pharmaceuticals, Inc.宣布，安德鲁·C·陈博士正式加入公司董事会。陈博士在基因泰克拥有25年卓越职业生涯，近期担任研究生物学高级副总裁，主导跨治疗领域的生物学研究，推动多款获FDA批准的肿瘤学、神经学及免疫学药物研发。Corvus制药专注于开发ITK抑制技术，其核心候选药物soquelitinib是一种口服小分子ITK抑制剂，目前正进行针对复发/难治性外周T细胞淋巴瘤的3期注册临床试验，以及治疗特应性皮炎的2期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","CRVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180592946","title":"异动解读 | Corvus制药扩大股票销售协议，股价盘中大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180592946","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180592946?lang=zh_cn&edition=full","pubTime":"2026-03-13 23:05","pubTimestamp":1773414315,"startTime":"0","endTime":"0","summary":"生物技术公司Corvus Pharmaceuticals, Inc.今日盘中股价大跌5.18%，引起了市场的关注。新协议允许Corvus通过多种方式出售股票，包括私人交易和大宗交易。根据文件，杰富瑞将从出售的任何股票中获得最多3%的佣金，而Corvus尚未根据先前的协议出售任何股票。市场分析认为，扩大股票销售协议可能意味着公司计划进行更大规模的股权融资，这通常会稀释现有股东的权益，因此被视作利空消息。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CRVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189349786","title":"Corvus制药公司修订销售协议 拟发售最高2亿美元普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1189349786","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189349786?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:48","pubTimestamp":1773406094,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Corvus Pharmaceuticals, Inc. 已签署一项修订后的股权分销协议。该协议授权公司通过市场发行方式，出售价值最高达2亿美元的普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","CRVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619157037","title":"Corvus Pharmaceuticals, Inc.盘中异动 股价大跌5.56%报15.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619157037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619157037?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:21","pubTimestamp":1773325272,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日22时21分，Corvus Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.56%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.91%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发精准靶向对免疫细胞成熟和功能至关重要的蛋白质的候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312222112a46446a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312222112a46446a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","CRVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614742122","title":"Corvus Pharmaceuticals, Inc.盘中异动 大幅拉升5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614742122","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614742122?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:52","pubTimestamp":1771944778,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时52分，Corvus Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.40%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发精准靶向对免疫细胞成熟和功能至关重要的蛋白质的候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602242252589541d5a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602242252589541d5a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRVS","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606732023","title":"Corvus Pharmaceuticals, Inc.盘中异动 急速下跌5.26%报21.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606732023","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606732023?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:50","pubTimestamp":1769525450,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日22时50分，Corvus Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.26%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。其相关个股中，Biomx Inc.、阿诺医药、Acumen Pharmaceuticals, Inc.涨幅较大，Biomx Inc.、Vyome Holdings, Inc.、Genenta Science Spa较为活跃，换手率分别为948.85%、692.84%、218.21%，振幅较大的相关个股有Biomx Inc.、Genenta Science Spa、Kazia Therapeutics Limited，振幅分别为53.90%、29.23%、21.94%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发精准靶向对免疫细胞成熟和功能至关重要的蛋白质的候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127225051953e981a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127225051953e981a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","CRVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156623981","title":"Corvus Pharmaceuticals完成增发规模扩大后的普通股公开发行 承销商全额行使超额配售权 募集资金总额约2.01亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156623981","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156623981?lang=zh_cn&edition=full","pubTime":"2026-01-24 06:04","pubTimestamp":1769205859,"startTime":"0","endTime":"0","summary":"2026年1月23日，临床阶段生物制药公司Corvus Pharmaceuticals, Inc.宣布完成其扩大规模的承销公开发行。此次发行共售出9,085,778股普通股，其中包括承销商全额行使超额配售权认购的1,185,101股额外股份，每股公开发行价格为22.15美元。在扣除承销折扣、佣金及预估发行费用前，此次承销公开发行的总募集资金预计约为2.012亿美元，该金额已包含承销商行使超额配售权所获资金。本次发行的所有普通股均由Corvus公司提供。Jefferies和高盛担任此次发行的联席主承销商。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVS","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128755564","title":"Corvus制药公司暂停与杰富瑞的普通股发行计划 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1128755564","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128755564?lang=zh_cn&edition=full","pubTime":"2026-01-21 05:25","pubTimestamp":1768944316,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals, Inc.已决定暂停其与投资银行杰富瑞（Jefferies）之间的一项普通股发行计划。根据提交给美国证券交易委员会（SEC）的文件，该公司已正式中止了此项股票发售活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVS","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159492395","title":"Corvus Pharmaceuticals公布队列4积极数据 确认Soquelitinib治疗特应性皮炎安慰剂对照1期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1159492395","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159492395?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:03","pubTimestamp":1768910638,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals宣布，其队列4的积极数据进一步确认了Soquelitinib在治疗特应性皮炎的安慰剂对照1期临床试验中所取得的成果。这一进展为该公司在免疫疾病治疗领域的研发增添了重要砝码。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","CRVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114195675","title":"Corvus Pharmaceuticals将公布Soquelitinib治疗特应性皮炎安慰剂对照1期临床试验第四队列结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1114195675","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114195675?lang=zh_cn&edition=full","pubTime":"2026-01-17 05:02","pubTimestamp":1768597334,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals, Inc. (简称Corvus Pharmaceuticals) 即将公布其药物Soquelitinib用于治疗特应性皮炎的安慰剂对照1期临床试验中第四队列的研究结果。该公告备受业界关注，因其可能揭示该候选疗法在特定患者群体中的有效性与安全性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","CRVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143358648","title":"Corvus Pharmaceuticals确认计划于2026年1月年度医疗大会后公布Soquelitinib治疗特应性皮炎安慰剂对照1期临床试验第四队列结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1143358648","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143358648?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:30","pubTimestamp":1767619828,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals, Inc. (简称Corvus Pharmaceuticals) 已正式确认，计划在2026年1月举行的年度医疗大会之后，公布其候选药物Soquelitinib用于治疗特应性皮炎的安慰剂对照1期临床试验中第四队列的研究结果。\n这项关键临床进展的公布时间安排，凸显了公司对推进Soquelitinib临床开发计划的承诺。特应性皮炎作为一种常见的慢性炎症性皮肤病，存在大量未满足的医疗需求，Soquelitinib的研发进展因而备受市场关注。\n第四队列数据的披露，将为评估该药物的安全性和初步疗效提供重要依据，是项目推进过程中的一个里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVS","BK4139","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582826302","title":"Corvus Pharmaceuticals, Inc.2025财年第三财季实现净利润-10.16百万美元，同比增加74.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582826302","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582826302?lang=zh_cn&edition=full","pubTime":"2025-11-10 00:01","pubTimestamp":1762704096,"startTime":"0","endTime":"0","summary":"11月10日，Corvus Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第三财季净利润为-10.16百万美元，同比增加74.74%；其中营业收入为0.00美元，每股基本收益为-0.12美元。从资产负债表来看，Corvus Pharmaceuticals, Inc.总负债8.71百万美元，其中短期债务379000.00美元，资产负债比为9.24，流动比率为8.30。机构评级：截至2025年11月10日，当前有6家机构对Corvus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为15.33美元，其中最低目标价为11.00美元，最高目标价为24.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110000223a4950663&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110000223a4950663&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518272633","title":"Corvus Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518272633","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518272633?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:03","pubTimestamp":1741615414,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时03分，Corvus Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.19%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为672.40%、342.08%、93.86%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Pmgc Holdings Inc.，振幅分别为41.36%、40.24%、32.14%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220335a26a3104&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220335a26a3104&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRVS","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517164364","title":"Corvus Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517164364","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517164364?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:40","pubTimestamp":1741275643,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时40分，Corvus Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.33%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.49%。其相关个股中，Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Plus Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Aditxt, Inc.较为活跃，换手率分别为2212.44%、1590.75%、85.87%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Aeon Biopharma, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为68.33%、67.37%、49.27%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306234043963c5ac7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306234043963c5ac7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRVS","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514433086","title":"Corvus Pharmaceuticals, Inc.盘中异动 临近收盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514433086","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514433086?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:57","pubTimestamp":1740689829,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时57分，Corvus Pharmaceuticals, Inc.股票出现异动，股价急速下跌5.06%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.57%。其相关个股中，Pepgen Inc.、Ibio, Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1955.27%、424.52%、198.31%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。其他产品包括Ciforadenant 和Mupadolimab 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228045710a256d079&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228045710a256d079&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","CRVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514862265","title":"Corvus Pharmaceuticals, Inc.盘中异动 大幅拉升5.52%报4.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514862265?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:28","pubTimestamp":1740601714,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时28分，Corvus Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.52%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.69%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Salarius Pharmaceuticals, Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6844.95%、332.32%、265.02%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为194.07%、81.11%、70.39%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270428359893eace&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270428359893eace&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRVS","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514013012","title":"Corvus Pharmaceuticals, Inc.盘中异动 股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013012","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514013012?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:18","pubTimestamp":1740496685,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时18分，Corvus Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.13%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Lava Therapeutics N.V.涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1050.65%、845.70%、586.00%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp，振幅分别为121.95%、63.66%、61.16%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231805abdc89ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231805abdc89ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","CRVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513216438","title":"Corvus Pharmaceuticals, Inc.盘中异动 下午盘大幅下跌5.22%报4.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513216438","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513216438?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:42","pubTimestamp":1740163342,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时42分，Corvus Pharmaceuticals, Inc.股票出现波动，股价大幅跳水5.22%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。其相关个股中，Revolution Medicines Inc C/Wts 17/12/2026 、Osr Holdings, Inc.、Invivyd, Inc.涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为285.22%、247.28%、136.38%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222024222abd7e3aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222024222abd7e3aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRVS","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512431742","title":"Corvus Pharmaceuticals, Inc.盘中异动 临近收盘股价大跌5.14%报4.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512431742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512431742?lang=zh_cn&edition=full","pubTime":"2025-02-20 04:54","pubTimestamp":1739998480,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日04时54分，Corvus Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.14%。截至发稿，该股报4.53美元/股，成交量41.9916万股，换手率0.65%，振幅4.82%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.93%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220045440abd5422b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220045440abd5422b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRVS","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corvuspharma.com","stockEarnings":[{"period":"1week","weight":-0.0386},{"period":"1month","weight":0.0714},{"period":"3month","weight":-0.2531},{"period":"6month","weight":0.9229},{"period":"1year","weight":3.392},{"period":"ytd","weight":1.0078}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Corvus Pharmaceuticals, Inc.于2014年1月27日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，正在开发针对免疫细胞功能至关重要的蛋白质的候选产品。其主要候选药物soquelitinib旨在抑制ITK，目前正在临床试验中对包括T细胞淋巴瘤和特应性皮炎在内的病症进行评估。该公司的战略侧重于将其免疫学专业知识应用于具有重大未满足医疗需求的多个疾病领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.148514},{"month":2,"riseRate":0.3,"avgChangeRate":-0.060776},{"month":3,"riseRate":0.3,"avgChangeRate":-0.026271},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.063826},{"month":5,"riseRate":0.727273,"avgChangeRate":0.26811},{"month":6,"riseRate":0.3,"avgChangeRate":-0.062415},{"month":7,"riseRate":0.5,"avgChangeRate":0.054478},{"month":8,"riseRate":0.7,"avgChangeRate":0.146907},{"month":9,"riseRate":0.5,"avgChangeRate":0.106125},{"month":10,"riseRate":0.4,"avgChangeRate":0.017628},{"month":11,"riseRate":0.6,"avgChangeRate":0.004343},{"month":12,"riseRate":0.2,"avgChangeRate":-0.066236}],"exchange":"NASDAQ","name":"Corvus Pharmaceuticals, Inc.","nameEN":"Corvus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corvus Pharmaceuticals, Inc.(CRVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Corvus Pharmaceuticals, Inc.(CRVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Corvus Pharmaceuticals, Inc.,CRVS,Corvus Pharmaceuticals, Inc.股票,Corvus Pharmaceuticals, Inc.股票老虎,Corvus Pharmaceuticals, Inc.股票老虎国际,Corvus Pharmaceuticals, Inc.行情,Corvus Pharmaceuticals, Inc.股票行情,Corvus Pharmaceuticals, Inc.股价,Corvus Pharmaceuticals, Inc.股市,Corvus Pharmaceuticals, Inc.股票价格,Corvus Pharmaceuticals, Inc.股票交易,Corvus Pharmaceuticals, Inc.股票购买,Corvus Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corvus Pharmaceuticals, Inc.(CRVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Corvus Pharmaceuticals, Inc.(CRVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}